Results 21 to 30 of about 945,488 (321)
Iptacopan for Immune Thrombocytopenia and Cold Agglutinin Disease: A Global Phase 2 Basket Clinical Trial. [PDF]
Am J HematolABSTRACT Iptacopan is a first‐in‐class, oral, selective inhibitor of complement factor B that has demonstrated positive efficacy across several complement‐driven diseases. Here we evaluate the efficacy and safety of iptacopan monotherapy in adult patients with primary immune thrombocytopenia (ITP) and primary cold agglutinin disease (CAD). We performed
Röth A +13 more
europepmc +2 more sources
Blood, 2022 Röth and colleagues present results of a phase 3 trial of the C1s classical complement pathway inhibitor sutimlimab for the treatment of patients with cold agglutinin disease (CAD) who did not receive a transfusion within the previous 6 months.
A. Röth +18 more
semanticscholar +1 more source
Congenital cardiac surgery in a patient with cold agglutinins
Current Medicine Research and Practice, 2023 Cold agglutinin disease is a type of autoimmune haemolytic anaemia caused by autoantibodies that bind to red blood cell antigens at a cold temperature and causes extravascular haemolysis and sometimes thrombosis also.
Mridul Agarwal +3 more
doaj +1 more source
American journal of hematology/oncology, 2023 Cold agglutinin disease (CAD) is a rare, autoimmune, classical complement pathway (CP)‐mediated hemolytic anemia. Sutimlimab selectively inhibits C1s of the C1 complex, preventing CP activation while leaving the alternative and lectin pathways intact. In
A. Röth +17 more
semanticscholar +1 more source
Blood, 2023 Key Points • Riliprubart (SAR445088, BIVV020) was generally well tolerated in patients with cold agglutinin disease.• A single dose led to complement pathway inhibition, control of hemolysis, and improvement in anemia, sustained over 15 weeks.
S. D'Sa +9 more
semanticscholar +1 more source
Complement-directed therapy for cold agglutinin disease: sutimlimab
Expert Review of Hematology, 2023 Introduction Cold agglutinin disease (CAD) is a rare subtype of autoimmune hemolytic anemia defined as a distinct, low-grade lymphoproliferative disorder and characterized by the presence of immunoglobulin M (IgM) antibodies that recognize the ‘I ...
C. Broome
semanticscholar +1 more source
How I Treat Cold Agglutinin Disease.
Blood, 2021 The last decades have seen great progress in the treatment of cold agglutinin disease (CAD). Comparative trials are lacking, and recommendations must be based mainly on nonrandomized trials and will be influenced by personal experience.
S. Berentsen
semanticscholar +1 more source
Cold agglutinin disease: current challenges and future prospects
Journal of Blood Medicine, 2019 Sigbjørn Berentsen,1 Alexander Röth,2 Ulla Randen,3 Bernd Jilma,4 Geir E Tjønnfjord5–71Department of Research and Innovation, Haugesund Hospital, Haugesund, Norway; 2Department of Hematology, West German Cancer Center, University
Berentsen S +4 more
doaj +2 more sources
Sutimlimab Pharmacokinetics and Pharmacodynamics in Patients with Cold Agglutinin Disease
Journal of Pharmacology and Experimental Therapeutics, 2023 Sutimlimab, a humanized monoclonal antibody targeting the classic complement pathway, is approved in the United States, Japan, and the European Union for the treatment of hemolytic anemia in adults with cold agglutinin disease.
T. Frank +5 more
semanticscholar +1 more source
Platelet Cold Agglutinins [PDF]
Blood, 1970 Abstract A "cold" platelet agglutinin is described which is present in plasma and serum, is greater than 100,000 in molecular weight, appears to be a protein of the immunoglobulin type, is adsorbed by platelets in the absence of bivalent cations, and reacts only at temperatures below 34°C.
S P, Watkins, N R, Shulman
openaire +2 more sources